标题
RET kinase inhibitors: a review of recent patents (2012–2015)
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 27, Issue 1, Pages 91-99
出版商
Informa UK Limited
发表日期
2016-09-20
DOI
10.1080/13543776.2017.1238073
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer
- (2015) Minsoo Song JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
- (2014) I. Plaza-Menacho et al. CELLULAR SIGNALLING
- Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer
- (2014) Sheridan M. Hoy DRUGS
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Novel therapeutic targets in non-small cell lung cancer
- (2013) Muhammad Alamgeer et al. CURRENT OPINION IN PHARMACOLOGY
- RET inhibition: implications in cancer therapy
- (2013) Maria Grazia Borrello et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
- (2013) Luca Mologni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2012) Xuelin Huang et al. CANCER
- Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
- (2012) Arvin C. Dar et al. NATURE
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- Development of RET Kinase Inhibitors for Targeted Cancer Therapy
- (2011) L. Mologni CURRENT MEDICINAL CHEMISTRY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors
- (2010) Luca Mologni et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Targeting RET Receptor Tyrosine Kinase Activation in Cancer
- (2010) J. E. Phay et al. CLINICAL CANCER RESEARCH
- Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activityin Vitroandin Vivoin Papillary Dedifferentiated Thyroid Cancer
- (2010) Alessandro Antonelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting RET for thyroid cancer therapy
- (2008) Cinzia Lanzi et al. BIOCHEMICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now